Aktuellt
SENASTE
Redeye’s takeaway from Biovica's Q3 interim report is positive: The 510(k) review for DiviTum is progressing, clinical activities are expanding, and launch preparations pick up. Biovica expects a decision from the FDA, and a US commercial partner, before the end of Q3. As a market clearance in the US seems to draw closer, we raise our base case to SEK 46 (40).
LÄS MER
